WO2023022675A1 - Dispositif d'injection microfluidique et procédé d'utilisation dans la réparation de cartilage - Google Patents

Dispositif d'injection microfluidique et procédé d'utilisation dans la réparation de cartilage Download PDF

Info

Publication number
WO2023022675A1
WO2023022675A1 PCT/TR2021/050837 TR2021050837W WO2023022675A1 WO 2023022675 A1 WO2023022675 A1 WO 2023022675A1 TR 2021050837 W TR2021050837 W TR 2021050837W WO 2023022675 A1 WO2023022675 A1 WO 2023022675A1
Authority
WO
WIPO (PCT)
Prior art keywords
injection device
microfluidic injection
fluid
set forth
microfluidic
Prior art date
Application number
PCT/TR2021/050837
Other languages
English (en)
Inventor
Mahir MAHIROGULLARI
Oguzhan GUNDUZ
Original Assignee
Nanortopedi Teknoloji Sanayi Ve Ticaret A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanortopedi Teknoloji Sanayi Ve Ticaret A.S. filed Critical Nanortopedi Teknoloji Sanayi Ve Ticaret A.S.
Priority to PCT/TR2021/050837 priority Critical patent/WO2023022675A1/fr
Priority to EP21783601.4A priority patent/EP4387761A1/fr
Publication of WO2023022675A1 publication Critical patent/WO2023022675A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/20—Mixing gases with liquids
    • B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
    • B01F23/232—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids using flow-mixing means for introducing the gases, e.g. baffles
    • B01F23/2323—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids using flow-mixing means for introducing the gases, e.g. baffles by circulating the flow in guiding constructions or conduits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/20—Mixing gases with liquids
    • B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
    • B01F23/237—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media
    • B01F23/2373—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media for obtaining fine bubbles, i.e. bubbles with a size below 100 µm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/50—Movable or transportable mixing devices or plants
    • B01F33/501—Movable mixing devices, i.e. readily shifted or displaced from one place to another, e.g. portable during use
    • B01F33/5011—Movable mixing devices, i.e. readily shifted or displaced from one place to another, e.g. portable during use portable during use, e.g. hand-held
    • B01F33/50112—Movable mixing devices, i.e. readily shifted or displaced from one place to another, e.g. portable during use portable during use, e.g. hand-held of the syringe or cartridge type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions

Definitions

  • the present invention relates to a microfluidic injection device for creating microbubbles using multiple fluids containing bioactive materials and biocompatible gases for use in cartilage repair.
  • Articular cartridge has limited intrinsic regeneration and healing capacity, which makes joint arthroplasty an unavoidable surgical intervention (Makris, Eleftherios A., et al. "Repair and tissue engineering techniques for articular cartilage.” Nature Reviews Rheumatology 11.1 (2015): 21).
  • Chondral defects may be caused by micro breaks in the cartilage or trauma, repeated microtrauma or injuries by foreign objects. These types of injuries cannot be repaired with sufficient regeneration via intrinsic metabolic activity without blood and will develop into osteochondral defects. Osteochondral defects are defects that go past the tidemark (the transition zone between cartilage and bone) and into the bone. The reduction in the number of chondrocytes and progenitor cells as well as in metabolic activity with advanced age causes problems in the healing of cartilage tissue.
  • injectable viscoelastic biomaterials are used in the treatment of defects in cartilage tissue (Athanasiou, Kyriacos A., Eric M. Darling, and Jerry C. Hu. "Articular cartilage tissue engineering.” Synthesis Lectures on Tissue Engineering 1.1 (2009): 1-182).
  • This method consists of injecting a biomaterial to the defect site via a needle.
  • Injectable products available to be used in cartilage repair can be exemplified by BST-CarGel ve CartiFill. These products make use of injecting biomaterials into the cartilage defect area via a delivery needle (Shive, Matthew S., et al. "BST-CarGel: in situ chondroinduction for cartilage repair.” Operative Techniques in Orthopaedics 16.4 (2006): 271-278).
  • WO 2008/064487 discloses a method for repairing or regenerating tissues in a patient such as cartilage, meniscus, ligament, tendon, and bone.
  • the method comprises the step of administering simultaneously or sequentially a pro-coagulant factor and an effective amount of a polymer composition comprising a biocompatible polymer and blood or a component thereof.
  • a pro-coagulant factor When the polymer composition is in contact with the pro-coagulant factor it is converted into a non-liquid state such that the polymer composition will adhere to the site in need of repair to aid in the repair and/or regeneration of the tissue.
  • WO 2005/060987 discloses a cartilage therapeutic composition, capable of being clinically transplanted to clinically significant, symptomatic cartilage defects in human or animal hosts.
  • the cartilage therapeutic composition comprises a mixture of components of chondrocytes isolated and expanded or differentiated from a host such as human or animal, and thrombin and a fibrinogen matrix containing fibrinogen.
  • the document also discloses a method of using the cartilage therapeutic composition such that a mixture of thrombin, chondrocyte components and a fibrinogen matrix is injected to a cartilage defect
  • the present invention aims to improve on the problems in the prior art. Specifically, the invention makes use of microfluidics to generate microbubbles and creating a scaffold containing cells, and medicaments if needed, directly in the cartilage defect site in order to provide an improved treatment process for cartilage repair.
  • microfluidics and microbubbles to deliver therapeutic agents and generate scaffolds for cell cultures has been studied in the art.
  • US 8,679,051 discloses methods and medical devices for generating and stabilizing micro- or nano-bubbles, and systems and methods for therapeutic applications using the bubbles.
  • the micro-bubbles may be used to enhance therapeutic benefits such as ultrasound-guided precision drug delivery and real-time verification.
  • US 2011/091972 discloses methods and apparatuses for using microfluidics to generate bubbles and using the generated bubbles to construct scaffolds and cell-holding structures for culturing biological samples or analytes.
  • a scaffold for growing cells is provided to include a matrix of interconnected cavities formed from mixing a gas and a liquid containing a cross linkable material to produce a matrix of gas bubbles of substantially the same size and cross linking the cross linkable material to form a structure in which cells can be grown.
  • this system makes use of a micropipette technique and is most suitable for creating scaffold where cells can be cultured experimentally and not suitable to provide the precision that is required for direct application to a defect site.
  • the present invention discloses a microfluidic injection device that can be used in cartilage repair.
  • the microfluidic injection device of the present invention allows the use of composite and biological agents (including but not limited to stem cells and platelet-rich plasma), which are injected using the microbubble technique.
  • the microfluidic injection device uses CO2 gas, which allows a scaffold to be produced directly in the cartilage defect site during application in the perioperative phase. CO2 aids in the production of microbubbles and when the bubbles pop, they leave behind a porous scaffold in the defect site that cells can adhere to and propagate, and the damaged part of the cartilage can be regenerated with patient's own stem cells. The problem of slow regeneration of cartilage tissue will be boosted by stem cells and the patient will recover faster.
  • the microfluidic injection device can be used arthroscopically, which minimizes the inconvenience caused to the patient.
  • the microfluidic injection device of the present invention alleviates the problems associated with the methods and devices currently available in the art and provides a system that is convenient for doctors to use, improves the chances of healing and speeds up the treatment process.
  • the microfluidic injection device also comprises an electronic panel whereby the doctor can adjust parameters such as flowrate, gas pressure and fill rate during application.
  • the microfluidic injection device of the invention is used to fill defects in cartilage and/or bone with a suitable scaffold architecture and provides medication and/or cells to the area as needed.
  • Figure 1 illustrates an exploded view of a microfluidic injection device in accordance with the present invention.
  • Figure 2 illustrates a side (A) and front (B) view of a microfluidic injection device in accordance with the present invention.
  • Figure 3 illustrates a front (A), sectional across A-A (B), bottom (C), side (D), perspective (E) and sectional across B-B(F) view of a mixing element of a microfluidic injection device with a gas inlet in accordance with the present invention.
  • Figure 4 illustrates a sectional across B-B (A), side (B), perspective (C), front (D), bottom (E), back (F) and sectional across A-A (G) view of a microbubble production element of a two-piece mixing element of a microfluidic injection device with a gas inlet in accordance with the present invention.
  • Figure 5 illustrates a bottom (A), side (B), side (C) and perspective (D) view of a housing attachment element of a two-piece mixing element of a microfluidic injection device without a gas inlet as not covered by the present invention.
  • Figure 6 illustrates a front (A), front sectional (B), bottom (C), side (D), and side sectional (E) view of a mixing element of a microfluidic injection device without a gas inlet as not covered by the present invention.
  • Figure 7 illustrates a side (A), perspective (B), front (C), bottom (D) and sectional across A-A (E) view of a microbubble production element of a two- piece mixing element of a microfluidic injection device without a gas inlet as not covered by the present invention.
  • TGF growth factors
  • FGF FGF
  • IGF IGF
  • PDGF cytokines
  • nonprotein chemical compounds are extensively employed to facilitate cartilage tissue growth.
  • the present invention aims to provide a microfluidic injection device (1) that can be used to deliver the cells and the building blocks of the tissue scaffold directly onto the cartilage.
  • FIGS 1 and 2 show a microfluidic injection device (1) suitable to be used in the repair of defects in cartilage and bone tissue according to the present invention.
  • Said microfluidic injection device (1) comprises a housing (13), an actuator (11), at least one syringe (6) fixed onto a fixing element (7) and a mixing element (2).
  • the drive from the actuator (11) is transferred to the fixing element (8) attached to the syringes (6) via a gear assembly comprising an actuator gear (12), a gear (9) and a threaded shaft (11) and a pressing element (8).
  • the mixing element is attached to the housing (13) via fastening handles (15) and fastening holes (14) respectively.
  • the syringes (6) are attached to the mixing element (2) via the fluid inlets (3).
  • microfluidic injection device (1) comprises a plurality of syringes (6). In a more preferred embodiment of the present invention, microfluidic injection device (1) comprises 1 to 6 syringes (6). In a more preferred embodiment of the present invention, microfluidic injection device (1) comprises 2 or 3 syringes (6).
  • the actuator (11) pushes the syringes (6) and transfers the fluids therein into the mixing element (2).
  • These fluids may be hydrogels containing bioactive materials and cells that are known in the art of cartilage repair.
  • the fluids contain a cell solution for providing the growth of cartilage tissue in the damage site.
  • the cell solution consists of materials selected from chondrocytic cell lines, pluripotent stem cell lines, platelet-rich plasma, stromal vascular fraction, bone marrow aspirate concentrate, and combinations thereof cultured in suitable buffer known in the art.
  • cell solution further contains signaling molecules such as growth factors (TGF, FGF, IGF, PDGF), cytokines and nonprotein chemical compounds.
  • the fluids contain a biomaterial solution for building a tissue scaffold for cartilage tissue.
  • a biomaterial solution for building a tissue scaffold for cartilage tissue.
  • Many natural biomaterials have been widely used for cartilage tissue engineering such as collagen, gelatin, polysaccharides (alginate, agarose, chitosan, hyaluronic acid), and fibrin.
  • Collagen is any of a family of extracellular matrix (ECM) proteins occurring as a major component of connective tissue, giving it strength and flexibility.
  • ECM extracellular matrix
  • Collagen has advantages such as low antigenicity, high biocompatibility and bioabsorbability, adhesion to cells, cell growth, cell differentiation induction, blood coagulation, a styptic effect, and biocompatibility with other polymers.
  • collagen can be gelated physically or chemically so it can be used alone or with other biomaterials.
  • synthetic biomaterials such as poly(o-hydroxy esters) such as PGA, PLA and their copolymers are the most widely investigated synthetic biodegradable polymers for cartilage tissue engineering (Lee, Soo-Hong, and Heungsoo Shin. "Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering.” Advanced drug delivery reviews 59.4-5 (2007): 339-359).
  • the biomaterial is a biocompatible polymer selected from collagen, fibrin, chitosan, chitin, hyaluronan, alginate, glycosaminoglycan, chondroitin sulfate, keratan sulfate, dermatan sulfate, heparin, cellulose, heparin sulfate, polyacrylamide, polycaprolactone, polylactic acid, poly lactic-co-glycolic acid, polyvinyl alcohol, polyethylene glycol and combinations thereof.
  • the biomaterial is dissolved in distilled water, saline, organic or inorganic phosphate buffer, or any other suitable buffer known in the art.
  • the cell solution and the biomaterial solution may be mixed before loading into the syringes (6), or they may be loaded into the syringes (6) separately and mixed in the mixing element (2).
  • the solutions are loaded into the syringes (6) separately and mixed in the mixing element (2).
  • the fluids also contain therapeutic agents such as antibiotics and anticancer medications.
  • the fluids also crosslinking agents and surfactants in order to promote the generation of or the stability of the bubbles.
  • the fluids also contain citrates and EDTA.
  • Figure 3 shows a mixing element (2) of a microfluidic injection device (1) having a gas inlet according to the present invention.
  • the mixing element comprises at least one fluid inlet (3), at least one gas inlet (4), at least one fluid channel (18), a mixing point (19), at least one microbubble channel (18) and a microbubble fluid outlet (5).
  • mixing element (2) comprises a plurality of fluid inlets (2) and fluid channels (18).
  • mixing element (2) comprises 1 to 6 fluid inlets (2) and fluid channel (18).
  • mixing element (2) comprises 2 or 3 fluid inlets (2) and fluid channel (16).
  • the actuator (11) pushes multiple syringes (6) simultaneously in a controlled manner and the material within the syringes are transferred to the mixing element (2) via fluid inlets (3), wherein they flow through fluid channels (16) mix with each other in the mixing point (19).
  • the mixing element has a gas inlet (4) whereby CO2 gas is introduced into the mixing point (19) via a gas channel (17) from a gas supply with a regulator, which can be controlled by the operator of the microfluidic injection device (1).
  • the gas inlet (4) may be positioned at different angles vertically or horizontally and may be facing the front or the back.
  • the gas supply may be connected to the gas inlet (4) via a locking or a luer fitting.
  • CO2 gas is medical grade CO2. Use of CO2 gas is beneficial to the growth of cartilage tissue.
  • Microbubbles are formed at the mixing point (19) where the fluids and gas are injected vertically, horizontally or at an angle via the fluid channels (16) and gas channels (17) respectively.
  • An important advantage of not mixing the different solutions with each other before adding the gas and instead forming the microbubbles as the different fluids are mixing for the first time is that it is possible to obtain bubbles that are covered by the different solutions in a layerwise manner without mixing with each other. This is advantageous with fluids which may have an undesirable interaction with each other, such as precipitating out of the solution and blocking the channels of the mixing element (2).
  • fluid channels (16) and gas channel (17) enter the mixing point (19) at an angle of 20-70°.
  • the size of the microbubbles can be controlled by controlling the gas pressure, fluid flowrate, the diameter of the fluid channels (16) and the angle by which fluid channels (16) and gas channel (17) enter the mixing point (19).
  • Microbubble size is also dependent on the surface pressure and the viscosity of the fluid. For example, microbubble size decreases with increasing gas pressure. As another example, microbubble size decreases by increasing the angle by which fluid channels (16) and gas channel (17) enter the mixing point (19).
  • Microbubbles used in biomedical applications are preferably at least 10 pm in diameter, which is equivalent to the diameter of a red blood cell, in order to obtain similar rheology in the micro vessels and capillary vessels of the subject.
  • the microbubbles formed are 10-500 pm in diameter. In an even more preferred embodiment of the invention, the microbubbles formed are 10-300 pm in diameter.
  • the fluid flowrate in fluid channels (16) is 600 pl/min and the gas pressure is 30-600 kPa to form microbubbles of desired size.
  • microbubble fluid outlet (5) can be attached to a needle whereby the fluid containing microbubbles, can be applied directly to the damage site, creating a tissue scaffold containing bioactive materials that is suitable to be used in cartilage repair, and adheres there more efficiently due the gas pressure.
  • microbubble fluid outlet (5) can be attached to other injection means, such as a catheter, tube, or other surgical instrument that can be inserted within a body to a point of interest.
  • the microfluidic injection device (1) comprises a two-piece mixing element (2") comprises a housing attachment element (20) and a microbubble production element (21) ( Figures 4 and 5).
  • mixing element (2') of a microfluidic injection device (1) does not comprise a gas inlet ( Figures 6 and 7).
  • the device can be used to mix the fluids containing biomaterials and/or cells without generating microbubbles.
  • a doctor can use the handheld microfluidic injection device (1) to position the needle, or other injection means, at the desired cartilage damage site and deposit the microbubble fluid directly thereonto in a practical and efficient manner.
  • the actuator (11) when in operation, pushes the syringes (6) at a speed of 20-40 ml/s on average.
  • the actuator (11) is a 5 N/m 12 V reductor motor, servo motor, brushed de motor, a step motor or any suitable motor known in the art.
  • the syringes (6) can be removed to be refilled with the desired fluids.
  • parameters including but not limited to fluid flowrate and gas pressure can be monitored using the OLED screen of the microfluidic injection device and the actuator (11) can be controlled by an electronic card having an H-bridge, a DC-DC boost converter and a microprocessor.
  • Control systems such as PID are controlled by PWM.
  • the direction of the motor is determined by the H-bridge and depending on the clockwise and/or counterclockwise direction of the motor, the syringes are moved forward or backward.
  • a limit switch is utilized to determine if the syringes (6) have reached the start and end points.
  • the microfluidic injection device (1) operates using a rechargeable lithium battery.
  • the present invention proposes a microfluidic injection device (1) for generating microbubbles, comprising a housing (13) housing an actuator (11), at least one syringe (6) fixed onto a fixing element (7) and a mixing element (2), wherein said syringe (6) is preloaded with a biocompatible fluid component, said mixing element (2) comprises at least one fluid inlet (3) whereby at least one syringe is attached (6) to said mixing element (2), at least one fluid channel (16), a mixing point (19) and a microbubble channel (18) in fluid communication with said fluid inlet (3) and syringe (6), said mixing element (2) comprises a gas inlet (4) and a gas channel (17) in fluid communication with said mixing point (19) whereby said gas component is loaded into said mixing element (2), said actuator (11) is configured to facilitate the pushing of said fixing element (7) against said syringe (6) whereby the contents of said syringe (6) are transferred into and travel along said fluid channel (16) to said mixing point (19).
  • said mixing element (2) comprises between 1 and 6 fluid inlets (3) whereby between 1-6 syringes (6) can be attached to said mixing element (2).
  • said fluid channels (16) enter the mixing point (19) at an angle between 20-70°.
  • the microbubbles formed by said microfluidic injection device (1) are 10-500 pm in diameter.
  • the microbubbles formed by said microfluidic injection device (1) are 10-300 pm in diameter.
  • said biocompatible fluid component is a cell solution, a biomaterial solution, or a combination thereof.
  • said cell solution comprises materials selected from chondrocytic cell lines, pluripotent stem cell lines, platelet-rich plasma, stromal vascular fraction, bone marrow aspirate concentrate, and combinations thereof cultured in a suitable buffer solution.
  • said cell solution comprises materials selected from growth factors, cytokines and combinations thereof.
  • said biomaterial solution comprises a biocompatible polymer selected from collagen, fibrin, chitosan, chitin, hyaluronan, alginate, glycosaminoglycan, chondroitin sulfate, keratan sulfate, dermatan sulfate, heparin, cellulose, heparin sulfate, polyacrylamide, polycaprolactone, polylactic acid, poly lactic-co-glycolic acid, polyvinyl alcohol, polyethylene glycol and combinations thereof dissolved in suitable buffer solution.
  • a biocompatible polymer selected from collagen, fibrin, chitosan, chitin, hyaluronan, alginate, glycosaminoglycan, chondroitin sulfate, keratan sulfate, dermatan sulfate, heparin, cellulose, heparin sulfate, polyacrylamide, polycaprolactone, polylactic acid, poly lactic
  • said biocompatible fluid component comprises therapeutic agents, crosslinking agents, surfactants, or combinations thereof.
  • said biocompatible fluid component comprises citrates, EDTA, or combinations thereof.
  • said gas component comprises medical grade carbon dioxide gas.
  • said mixing element (2") has a two-piece structure comprising a housing attachment element (20) and a microbubble production element (21).
  • said injection means is a needle.
  • the present invention also proposes a method for generating tissue scaffolds for use in cartilage repair, comprising the steps of:
  • microfluidic injection device (1) according to any one of Claims 1 to 14 with at least one biocompatible fluid component and at least one gas component,
  • microfluidic injection device (1) using said microfluidic injection device (1) to generate bubbles within said biocompatible fluid component to be introduced to a point of interest in a cartilage defect.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne un dispositif d'injection microfluidique pour créer des microbulles à l'aide de multiples fluides contenant des matériaux bioactifs, comprenant, mais sans y être limités, des cellules souches, des biomatériaux et des gaz biocompatibles pour une utilisation dans la réparation de cartilage. Le dispositif d'injection microfluidique selon la présente invention atténue les problèmes associés aux procédés et dispositifs actuellement disponibles dans l'état de la technique et fournit un système qui est pratique pour les médecins à utiliser, améliore les chances de cicatrisation et accélère le processus de traitement.
PCT/TR2021/050837 2021-08-19 2021-08-19 Dispositif d'injection microfluidique et procédé d'utilisation dans la réparation de cartilage WO2023022675A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/TR2021/050837 WO2023022675A1 (fr) 2021-08-19 2021-08-19 Dispositif d'injection microfluidique et procédé d'utilisation dans la réparation de cartilage
EP21783601.4A EP4387761A1 (fr) 2021-08-19 2021-08-19 Dispositif d'injection microfluidique et procédé d'utilisation dans la réparation de cartilage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2021/050837 WO2023022675A1 (fr) 2021-08-19 2021-08-19 Dispositif d'injection microfluidique et procédé d'utilisation dans la réparation de cartilage

Publications (1)

Publication Number Publication Date
WO2023022675A1 true WO2023022675A1 (fr) 2023-02-23

Family

ID=78032479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/050837 WO2023022675A1 (fr) 2021-08-19 2021-08-19 Dispositif d'injection microfluidique et procédé d'utilisation dans la réparation de cartilage

Country Status (2)

Country Link
EP (1) EP4387761A1 (fr)
WO (1) WO2023022675A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060987A1 (fr) 2003-12-23 2005-07-07 Sewon Cellontech Co., Ltd. Composition pour la therapeutique du cartilage et son procede d'utilisation
US20060280690A1 (en) * 2003-11-17 2006-12-14 Wright David D I Methods of preparing a foam comprising a sclerosing agent
WO2008064487A1 (fr) 2006-11-30 2008-06-05 Bio Syntech Canada Inc. Méthode de solidification in situ de compositions sang-polymère pour médecine régénérative et applications de réparation du cartilage
US20110091972A1 (en) 2009-10-20 2011-04-21 Academia Sinica Fabricating Scaffolds and Other Cell-Growth Structures Using Microfluidics to Culture Biological Samples
US8679051B2 (en) 2005-10-27 2014-03-25 Artenga Inc Microbubble medical devices

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280690A1 (en) * 2003-11-17 2006-12-14 Wright David D I Methods of preparing a foam comprising a sclerosing agent
WO2005060987A1 (fr) 2003-12-23 2005-07-07 Sewon Cellontech Co., Ltd. Composition pour la therapeutique du cartilage et son procede d'utilisation
US8679051B2 (en) 2005-10-27 2014-03-25 Artenga Inc Microbubble medical devices
WO2008064487A1 (fr) 2006-11-30 2008-06-05 Bio Syntech Canada Inc. Méthode de solidification in situ de compositions sang-polymère pour médecine régénérative et applications de réparation du cartilage
US20110091972A1 (en) 2009-10-20 2011-04-21 Academia Sinica Fabricating Scaffolds and Other Cell-Growth Structures Using Microfluidics to Culture Biological Samples

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ATHANASIOU, KYRIACOS A.ERIC M. DARLINGJERRY C. HU: "Articular cartilage tissue engineering.", SYNTHESIS LECTURES ON TISSUE ENGINEERING, vol. 1, no. 1, 2009, pages 1 - 182
GOMOLL, ANDREAS H.TOM MINAS: "The quality of healing: articular cartilage.", WOUND REPAIR AND REGENERATION, vol. 22, 2014, pages 30 - 38
LEE, SOO-HONG, HEUNGSOO SHIN: "Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering.", ADVANCED DRUG DELIVERY REVIEWS, vol. 59, no. 4-5, 2007, pages 339 - 359, XP022110913, DOI: 10.1016/j.addr.2007.03.016
MAKRIS, ELEFTHERIOS A. ET AL.: "Repair and tissue engineering techniques for articular cartilage.", NATURE REVIEWS RHEUMATOLOGY, vol. 111, 2015, pages 21
REDMAN, S. N.S. F. OLDFIELDC. W. ARCHER: "Current strategies for articular cartilage repair.", EUR CELL MATER, vol. 9, no. 23-32, 2005, pages 23 - 32
SHIVE, MATTHEW S. ET AL., TECHNIQUES IN ORTHOPAEDICS, vol. 16, no. 4, 2006, pages 271 - 278

Also Published As

Publication number Publication date
EP4387761A1 (fr) 2024-06-26

Similar Documents

Publication Publication Date Title
Wei et al. Articular cartilage and osteochondral tissue engineering techniques: Recent advances and challenges
Zippel et al. Biomaterials and mesenchymal stem cells for regenerative medicine
US9486317B2 (en) Method of arthroscopic osteochondral resurfacing using PRP strengthened with fibrin glue
EP2099509B1 (fr) Procédés et compositions servant à traiter un tissu en utilisant des protéines de soie
Schmitt et al. Application of stem cells in orthopedics
CN1471412B (zh) 用于修复和再生软骨和其它组织的组合物以及该组合物的用途
US7442389B2 (en) Methods of administering microparticles combined with autologous body components
CA2684040C (fr) Procede de formation d'un implant a l'aide d'un moule imitant la forme du site tissulaire defectueux et implant forme a partir de celui-ci
CN102573790B (zh) 用于产生白介素‑1受体拮抗剂的可植入装置
CN110177584B (zh) 低温凝胶3d支架及其生产方法
US20070116680A1 (en) Stem cells within gel microenvironments
EP2851096B1 (fr) Composition pour réparer un tissu cartilagineux, procédé pour la produire et son utilisation
DE69930155T2 (de) Spray verabreichung von zellen
RU2491076C2 (ru) Способ и композиция для регенерации тканей с помощью стволовых или костномозговых клеток
KR20080113013A (ko) 다공성 칼슘 포스페이트 뼈물질
KR102114300B1 (ko) 최소 침습 골연골 재생용 자기 구동 마이크로지지체
Babu et al. Controlling structure with injectable biomaterials to better mimic tissue heterogeneity and anisotropy
Rey et al. Fabrication techniques of tissue engineering scaffolds
Walker et al. Advances in progenitor cell therapy using scaffolding constructs for central nervous system injury
Tang et al. Using platelet-rich plasma hydrogel to deliver mesenchymal stem cells into three-dimensional PLGA scaffold for cartilage tissue engineering
Rahman et al. Tissue engineering of articular cartilage: From bench to bed-side
CN111187749A (zh) 用于快速再生血管化组织的人工结构体及构建方法与应用
WO2022133429A1 (fr) Matériaux particulaires pour mimétiques de tissu
CN110404117B (zh) 一种功能化引导肌组织修复膜及其制备方法和应用
WO2023022675A1 (fr) Dispositif d'injection microfluidique et procédé d'utilisation dans la réparation de cartilage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21783601

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021783601

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021783601

Country of ref document: EP

Effective date: 20240319